Cyclo Therapeutics completed a strategic corporate merger with Rafael Holdings, combining operations to further advance the clinical development of its lead drug candidate, Trappsol Cyclo, targeting Niemann-Pick Disease Type C. Following the completion of this merger and subsequent shareholder approvals, the unified enterprise continued conducting critical late-stage clinical investigations, including its pivotal global Phase 3 TransportNPC study and associated open-label sub-studies. These initiatives paved the way for progressive regulatory milestones, pre-NDA communications with health authorities, and ongoing data presentations.
Acrow Limited operates as a leading specialist provider of construction engineering solutions, equipment rentals, and formwork systems for the civil, commercial, and industrial building sectors. Its core operational activities involve supplying heavy-duty scaffolding, falsework, screen systems, and specialized industrial access engineering services that allow contractors to complete complex infrastructure projects safely and efficiently. By combining equipment hire models with in-house engineering expertise, the company supports major national building pipelines without requiring heavy upfront asset purchases from its clients.